ResMed (NYSE: RMD) is expected to report Q3 earnings on April 25. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ResMed's revenues will grow 10.8% and EPS will grow 21.7%.

The average estimate for revenue is $386.8 million. On the bottom line, the average EPS estimate is $0.56.

Revenue details
 Last quarter, ResMed logged revenue of $376.5 million. GAAP reported sales were 13% higher than the prior-year quarter's $332.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.54. GAAP EPS of $0.53 for Q2 were 26% higher than the prior-year quarter's $0.42 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 61.8%, 210 basis points better than the prior-year quarter. Operating margin was 24.5%, 430 basis points better than the prior-year quarter. Net margin was 20.7%, 180 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.52 billion. The average EPS estimate is $2.24.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 195 members out of 211 rating the stock outperform, and 16 members rating it underperform. Among 63 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 60 give ResMed a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $41.66.

Is ResMed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.